Mark Bach
Chief Tech/Sci/R&D Officer en STRUCTURE THERAPEUTICS INC. .
Fortuna: 61 712 $ al 31/03/2024
Perfil
El Dr. Mark A. Bach, MD, es Vicepresidente Senior de Desarrollo Clínico en Ascendis Pharma A/S. Anteriormente, el Dr. Bach fue director ejecutivo de Accumulus Synergy, Inc., director de Ciencias Médicas en Asia-Pacífico de Janssen Pharmaceuticals, Inc., vicepresidente de Investigación y Desarrollo de Janssen Pharmaceutical KK, y vicepresidente de Operaciones de Investigación Clínica en todo el mundo de Merck & Co. Se licenció en el Carleton College, se doctoró en la Universidad de Chicago y se doctoró en el Baylor College of Medicine.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 15/03/2024 | 4 320 ( 0.00% ) | 61 712 $ | 31/03/2024 |
Cargos activos de Mark Bach
| Empresas | Cargo | Inicio |
|---|---|---|
| STRUCTURE THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01/06/2021 |
Antiguos cargos conocidos de Mark Bach.
| Empresas | Cargo | Fin |
|---|---|---|
| Accumulus Synergy, Inc | Chief Executive Officer | 01/10/2020 |
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Corporate Officer/Principal | 01/08/2019 |
Janssen Pharmaceutical KK
 Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Chief Tech/Sci/R&D Officer | 01/11/2012 |
| MERCK & CO., INC. | Corporate Officer/Principal | 01/01/2010 |
| ASCENDIS PHARMA A/S | Chief Tech/Sci/R&D Officer | - |
Formación de Mark Bach.
| Carleton College | Undergraduate Degree |
| The University of Chicago | Doctorate Degree |
| Baylor College of Medicine | Doctorate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| STRUCTURE THERAPEUTICS INC. | Commercial Services |
| Empresas privadas | 3 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Janssen Pharmaceutical KK
Janssen Pharmaceutical KK Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals KK develops, manufactures, and markets prescription pharmaceutical products. The company was founded in 1978 and is located in Tokyo, Japan. | Health Technology |
| Accumulus Synergy, Inc |
- Bolsa de valores
- Insiders
- Mark Bach
